Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Gold nanoparticles are tiny spherical particles made out of gold atoms with sizes on nanometre scale. This is around 1,000 times smaller than the thickness of human hair.

23 Apr 2013

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

An Indiana University School of Medicine breast cancer surgeon is pursuing research that will utilize glass, gold, nanotechnology and Greek mythology hoping to vanquish breast cancer that has metastasized to the brain.

19 Apr 2013

EU-funded project examines environmental impact of nanosilver T-shirts

Silver has been used as biocide for medical purposes since the 1930s. Today nanometric size silver particles are used to prevent unpleasant odour caused by bacteria in sport shirts or socks.

15 Apr 2013

Novel nanoparticle-based approach enables more efficient delivery of siRNA drugs

New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge. A novel nanoparticle-based approach that enables more efficient delivery of siRNA drugs is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

12 Apr 2013

New device that detects breast cancer metastasis is extending its market reach

A device co-developed by a University of Houston (UH) physicist to detect the spread of breast cancer and allow physicians to better plan intervention is extending its market reach, bringing it another step closer to clinical trials in the U.S.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Nine Nobel laureates to present their research at American Chemical Society meeting

At least nine Nobel laureates have research that will be presented here this week during the 245th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

Research identifies important role of zinc in kidney stone formation

Kidney stones usually make their presence known suddenly, often sending a person to the hospital in excruciating pain. Each year in the U.S. more than a million people seek medical attention for kidney stones, technically called nephrolithiasis.

8 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

New technique for vaccine design could prove useful against HIV, other viral strains

A team led by scientists from The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) has unveiled a new technique for vaccine design that could be particularly useful against HIV and other fast-changing viruses.

30 Mar 2013

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

20 Mar 2013

Nanomedicines prevent tissue damage associated with atherosclerosis, other chronic diseases

Doses of medicine 100,000 times smaller than the diameter of a human hair prevent the tissue damage associated with atherosclerosis and other chronic diseases in mice.

20 Mar 2013

CHOP expert to receive Pediatric Oncology Award from ASCO

The American Society of Clinical Oncology today announced it will confer one of its highest awards on pediatric oncologist Garrett M. Brodeur, M.D., of the Cancer Center at The Children's Hospital of Philadelphia.

16 Mar 2013

New, inexpensive nano-biosensor can detect Listeria monocytogenes in food

The foodborne bacteria Listeria monocytogenes sickens about 2,500 people in the U.S. each year and many more worldwide, killing about 25-30% of those infected. Listeriosis is caused by eating food contaminated with L. monocytogenes, and current methods for detecting the bacteria are costly and time consuming.

13 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

Melittin-loaded nanoparticles can destroy human immunodeficiency virus

Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. Louis have shown.

8 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Nanoparticle News and Research

Further Reading

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

EU-funded project examines environmental impact of nanosilver T-shirts

Novel nanoparticle-based approach enables more efficient delivery of siRNA drugs

New device that detects breast cancer metastasis is extending its market reach

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Nine Nobel laureates to present their research at American Chemical Society meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Research identifies important role of zinc in kidney stone formation

IGDRASOL to present updates on Cynviloq at AACR annual meeting

New technique for vaccine design could prove useful against HIV, other viral strains

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

Nanomedicines prevent tissue damage associated with atherosclerosis, other chronic diseases

CHOP expert to receive Pediatric Oncology Award from ASCO

New, inexpensive nano-biosensor can detect Listeria monocytogenes in food

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Melittin-loaded nanoparticles can destroy human immunodeficiency virus

EpiCept fourth quarter revenue decreases to $0.1 million

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest Life Science News